10-Year registry tracks Real-World safety of weekly growth hormone in kids
NCT ID NCT06709040
First seen Apr 11, 2026 · Last updated Jun 09, 2026 · Updated 9 times
Summary
This study follows 500 children with growth hormone deficiency who are taking somapacitan (a once-weekly injection) as part of their normal medical care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes over 10 years. The goal is to understand the long-term safety of this treatment in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Glasgow
Glasgow, Scotland, United Kingdom
Conditions
Explore the condition pages connected to this study.